$PMN
ProMIS Neurosciences Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024015634 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $2.564M
YoY Change 124.47%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.435M
YoY Change 76.15%
Operating Profit -$4.400M
YoY Change 74.77%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $13.71M
YoY Change 8638.82%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings $9.276M
YoY Change -486.49%
Net Earnings / Revenue
Basic Earnings Per Share $0.31
Diluted Earnings Per Share $0.31
COMMON SHARES
Basic Shares Outstanding 32.69M 29.89M
Diluted Shares Outstanding 30.07M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $21.54M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.51M
YoY Change 37.25%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $24.51M
Total Long-Term Assets $0.00
Total Assets $24.51M
YoY Change 37.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.575M
YoY Change -81.28%
Accrued Expenses $1.060M
YoY Change -26.23%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.635M
YoY Change -73.25%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.635M
Total Long-Term Liabilities
Total Liabilities $17.24M
YoY Change 55.0%
SHAREHOLDERS EQUITY
Retained Earnings -$90.40M
YoY Change 0.56%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.273M
YoY Change
Total Liabilities & Shareholders Equity $24.51M
YoY Change 37.11%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $9.276M
YoY Change -486.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001374339
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 pmn Fair Value Assets Liabilities Level2 Transfers Amount
FairValueAssetsLiabilitiesLevel2TransfersAmount
0
CY2023Q4 pmn Fair Value Assets Liabilities Level2 Transfers Amount
FairValueAssetsLiabilitiesLevel2TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 pmn Fair Value Assets Liabilities Level2 Transfers Amount
FairValueAssetsLiabilitiesLevel2TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32689190
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18885254
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32689190
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18885254
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A6
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0647155
dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 200, 1920 Yonge Street
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1166667
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41429
dei Entity Registrant Name
EntityRegistrantName
PROMIS NEUROSCIENCES INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A6
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0647155
dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 200, 1920 Yonge Street
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
M4S 3E2
dei City Area Code
CityAreaCode
416
dei Entity Address City Or Town
EntityAddressCityOrTown
Toronto
dei Entity Address State Or Province
EntityAddressStateOrProvince
ON
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
M4S 3E2
dei City Area Code
CityAreaCode
416
dei Local Phone Number
LocalPhoneNumber
847-6898
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
PMN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Local Phone Number
LocalPhoneNumber
847-6898
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
PMN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32689190
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21536898
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12598146
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
32358
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
32358
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2941279
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
988641
CY2024Q3 us-gaap Assets Current
AssetsCurrent
24510535
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13619145
CY2024Q3 us-gaap Assets
Assets
24510535
CY2023Q4 us-gaap Assets
Assets
13619145
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1575235
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1059852
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1506526
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2635087
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9349662
CY2024Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
340090
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
422002
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
14262138
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
94185
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32689190
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21536898
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12598146
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
32358
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
32358
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2941279
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
988641
CY2024Q3 us-gaap Assets Current
AssetsCurrent
24510535
CY2024Q3 us-gaap Assets
Assets
24510535
CY2023Q4 us-gaap Assets
Assets
13619145
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1575235
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7843136
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1059852
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1506526
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2635087
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9349662
CY2024Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
340090
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
422002
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
14262138
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
94185
CY2024Q3 us-gaap Liabilities
Liabilities
17237315
CY2023Q4 us-gaap Liabilities
Liabilities
9865849
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1166667
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1166667
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32689190
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32689190
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-371184
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-371184
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90448866
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3753296
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24510535
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13619145
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2563774
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1142160
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6313373
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5658127
CY2024Q3 us-gaap Liabilities
Liabilities
17237315
CY2023Q4 us-gaap Liabilities
Liabilities
9865849
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1166667
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1166667
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32689190
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32689190
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18885254
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18885254
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98093270
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
97590426
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-371184
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-371184
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90448866
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93465946
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7273220
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3753296
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24510535
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13619145
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2563774
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1142160
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6313373
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5658127
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1870903
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1375380
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4511660
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4729969
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4434677
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2517540
us-gaap Operating Expenses
OperatingExpenses
10825033
us-gaap Operating Expenses
OperatingExpenses
10388096
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4434677
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2517540
us-gaap Operating Income Loss
OperatingIncomeLoss
-10825033
us-gaap Operating Income Loss
OperatingIncomeLoss
-10388096
CY2024Q3 pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
16969126
CY2023Q3 pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
119019
pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
17014080
pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
683568
CY2023Q3 us-gaap Interest Expense
InterestExpense
75413
us-gaap Interest Expense
InterestExpense
76775
us-gaap Interest Expense
InterestExpense
124595
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
235912
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
113286
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1870903
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1375380
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4511660
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4729969
us-gaap Operating Expenses
OperatingExpenses
10825033
us-gaap Operating Expenses
OperatingExpenses
10388096
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2517540
us-gaap Operating Income Loss
OperatingIncomeLoss
-10388096
CY2024Q3 pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
16969126
pmn Gain Loss From Change In Fair Value Of Financial Instruments
GainLossFromChangeInFairValueOfFinancialInstruments
683568
CY2023Q3 us-gaap Interest Expense
InterestExpense
75413
us-gaap Interest Expense
InterestExpense
76775
us-gaap Interest Expense
InterestExpense
124595
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
235912
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
113286
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
399344
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
197070
CY2024Q3 pmn Loss On Sale Of Common Shares And Warrants
LossOnSaleOfCommonSharesAndWarrants
3494536
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13710502
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
156892
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13842113
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
756043
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
9275825
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2360648
us-gaap Net Income Loss
NetIncomeLoss
-9632053
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-175815
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9275825
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2360648
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3017080
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9807868
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30023675
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12370830
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22953751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861719
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30067095
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12370830
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23676104
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9861719
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8528291
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1287400
CY2023Q3 pmn Adjustments To Additional Paid In Capital Warrant Reclassified Due To Change In Functional Currency
AdjustmentsToAdditionalPaidInCapitalWarrantReclassifiedDueToChangeInFunctionalCurrency
-396375
CY2023Q3 pmn Apic Share Based Payment Arrangement Equity Classified Stock Options To Share Based Compensation Liability Due To Change In Functional Currency
ApicShareBasedPaymentArrangementEquityClassifiedStockOptionsToShareBasedCompensationLiabilityDueToChangeInFunctionalCurrency
-1435913
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
399344
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
197070
CY2024Q3 pmn Loss On Sale Of Common Shares And Warrants
LossOnSaleOfCommonSharesAndWarrants
3494536
pmn Loss On Sale Of Common Shares And Warrants
LossOnSaleOfCommonSharesAndWarrants
3494536
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13710502
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
156892
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13842113
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
9275825
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2360648
us-gaap Net Income Loss
NetIncomeLoss
3017080
us-gaap Net Income Loss
NetIncomeLoss
-9632053
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-175815
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9275825
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2360648
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30023675
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12370830
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22953751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861719
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30067095
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12370830
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23676104
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9861719
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-8528291
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1287400
CY2023Q3 pmn Adjustments To Additional Paid In Capital Warrant Reclassified Due To Change In Functional Currency
AdjustmentsToAdditionalPaidInCapitalWarrantReclassifiedDueToChangeInFunctionalCurrency
-396375
CY2023Q3 pmn Apic Share Based Payment Arrangement Equity Classified Stock Options To Share Based Compensation Liability Due To Change In Functional Currency
ApicShareBasedPaymentArrangementEquityClassifiedStockOptionsToShareBasedCompensationLiabilityDueToChangeInFunctionalCurrency
-1435913
CY2023Q3 pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
443516
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2360648
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6754889
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2277078
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
121036
CY2024Q3 pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
125398
CY2024Q3 pmn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
28039
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
9275825
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7273220
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347772
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
266701
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-175815
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1287400
pmn Adjustments To Additional Paid In Capital Warrant Reclassified Due To Change In Functional Currency
AdjustmentsToAdditionalPaidInCapitalWarrantReclassifiedDueToChangeInFunctionalCurrency
-396375
pmn Apic Share Based Payment Arrangement Equity Classified Stock Options To Share Based Compensation Liability Due To Change In Functional Currency
ApicShareBasedPaymentArrangementEquityClassifiedStockOptionsToShareBasedCompensationLiabilityDueToChangeInFunctionalCurrency
-1435913
CY2023Q3 pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
443516
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2360648
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6754889
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2277078
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
121036
CY2024Q3 pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
125398
CY2024Q3 pmn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
28039
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
9275825
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7273220
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347772
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
266701
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-175815
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1287400
pmn Adjustments To Additional Paid In Capital Warrant Reclassified Due To Change In Functional Currency
AdjustmentsToAdditionalPaidInCapitalWarrantReclassifiedDueToChangeInFunctionalCurrency
-396375
pmn Apic Share Based Payment Arrangement Equity Classified Stock Options To Share Based Compensation Liability Due To Change In Functional Currency
ApicShareBasedPaymentArrangementEquityClassifiedStockOptionsToShareBasedCompensationLiabilityDueToChangeInFunctionalCurrency
-1435913
pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
443516
us-gaap Net Income Loss
NetIncomeLoss
-9632053
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6754889
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3753296
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202619
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
190274
pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
81912
pmn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
28039
us-gaap Net Income Loss
NetIncomeLoss
3017080
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7273220
us-gaap Profit Loss
ProfitLoss
3017080
us-gaap Profit Loss
ProfitLoss
-9632053
us-gaap Share Based Compensation
ShareBasedCompensation
202619
us-gaap Share Based Compensation
ShareBasedCompensation
266701
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2632
pmn Loss On Sale Of Common Shares And Warrants
LossOnSaleOfCommonSharesAndWarrants
3494536
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
17014080
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
683568
us-gaap Depreciation
Depreciation
322
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2816
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1452638
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-38897
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6267901
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5439199
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-446674
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2515120
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18467058
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7085438
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
190274
pmn Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
27187497
pmn Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
18259414
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
28039
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27405810
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18259414
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-181425
pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
443516
us-gaap Net Income Loss
NetIncomeLoss
-9632053
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6754889
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3753296
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202619
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
190274
pmn Apic Share Based Payment Arrangement Re Measurement Of Liability Classified Stock Options
ApicShareBasedPaymentArrangementReMeasurementOfLiabilityClassifiedStockOptions
81912
pmn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
28039
us-gaap Net Income Loss
NetIncomeLoss
3017080
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7273220
us-gaap Profit Loss
ProfitLoss
3017080
us-gaap Profit Loss
ProfitLoss
-9632053
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2632
pmn Loss On Sale Of Common Shares And Warrants
LossOnSaleOfCommonSharesAndWarrants
3494536
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
17014080
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
683568
us-gaap Depreciation
Depreciation
322
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2816
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1452638
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-38897
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6267901
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5439199
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-446674
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2515120
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18467058
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7085438
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
190274
pmn Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
27187497
pmn Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
18259414
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
28039
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27405810
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18259414
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-181425
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8938752
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10992551
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12598146
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5875796
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21536898
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16868347
pmn Conversion Of Convertible Debt And Derivative Liability To Series1 Convertible Preferred Shares
ConversionOfConvertibleDebtAndDerivativeLiabilityToSeries1ConvertiblePreferredShares
5600000
pmn Non Cash Share Issue Cost Included In Accrued Liabilities
NonCashShareIssueCostIncludedInAccruedLiabilities
514214
pmn Reclassification Of Warrants From Equity To Liability
ReclassificationOfWarrantsFromEquityToLiability
396375
pmn Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
1287400
pmn Subscription Amount Receivable
SubscriptionAmountReceivable
500000
pmn Share Based Compensation Liability Non Cash Financing Activities
ShareBasedCompensationLiabilityNonCashFinancingActivities
81912
pmn Other Interest Paid
OtherInterestPaid
76775
pmn Other Interest Paid
OtherInterestPaid
124595
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4400000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10800000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8938752
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10992551
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12598146
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5875796
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21536898
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16868347
pmn Conversion Of Convertible Debt And Derivative Liability To Series1 Convertible Preferred Shares
ConversionOfConvertibleDebtAndDerivativeLiabilityToSeries1ConvertiblePreferredShares
5600000
pmn Non Cash Share Issue Cost Included In Accrued Liabilities
NonCashShareIssueCostIncludedInAccruedLiabilities
514214
pmn Reclassification Of Warrants From Equity To Liability
ReclassificationOfWarrantsFromEquityToLiability
396375
pmn Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
1287400
pmn Subscription Amount Receivable
SubscriptionAmountReceivable
500000
pmn Share Based Compensation Liability Non Cash Financing Activities
ShareBasedCompensationLiabilityNonCashFinancingActivities
81912
pmn Other Interest Paid
OtherInterestPaid
76775
pmn Other Interest Paid
OtherInterestPaid
124595
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4400000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10800000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of warrant liabilities. Actual results could differ from those estimates, and such differences could be material to the unaudited condensed consolidated financial statements.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of warrant liabilities. Actual results could differ from those estimates, and such differences could be material to the unaudited condensed consolidated financial statements.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 pmn Fair Value Assets Liabilities Level1 Transfers Amount
FairValueAssetsLiabilitiesLevel1TransfersAmount
0
CY2023Q4 pmn Fair Value Assets Liabilities Level1 Transfers Amount
FairValueAssetsLiabilitiesLevel1TransfersAmount
0
CY2024Q3 pmn Prepaid Upfront Research Payments Current
PrepaidUpfrontResearchPaymentsCurrent
1777249
CY2023Q4 pmn Prepaid Upfront Research Payments Current
PrepaidUpfrontResearchPaymentsCurrent
146851
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
130283
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
78637
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
460549
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
482297
CY2024Q3 pmn Fair Value Assets Liabilities Level1 Transfers Amount
FairValueAssetsLiabilitiesLevel1TransfersAmount
0
CY2023Q4 pmn Fair Value Assets Liabilities Level1 Transfers Amount
FairValueAssetsLiabilitiesLevel1TransfersAmount
0
CY2024Q3 pmn Prepaid Upfront Research Payments Current
PrepaidUpfrontResearchPaymentsCurrent
1777249
CY2023Q4 pmn Prepaid Upfront Research Payments Current
PrepaidUpfrontResearchPaymentsCurrent
146851
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
130283
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
78637
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
460549
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
482297
CY2023Q4 pmn Prepaid Consultants Current
PrepaidConsultantsCurrent
21535
CY2024Q3 pmn Prepaid License Fee Current
PrepaidLicenseFeeCurrent
60208
CY2023Q4 pmn Prepaid License Fee Current
PrepaidLicenseFeeCurrent
30472
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
195632
CY2024Q3 pmn Share Subscribed Subscriptions Receivable Current
ShareSubscribedSubscriptionsReceivableCurrent
500000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
12990
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
33217
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2941279
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
988641
CY2024Q3 pmn Accrued Legal Fees Current
AccruedLegalFeesCurrent
69510
CY2023Q4 pmn Prepaid Consultants Current
PrepaidConsultantsCurrent
21535
CY2024Q3 pmn Prepaid License Fee Current
PrepaidLicenseFeeCurrent
60208
CY2023Q4 pmn Prepaid License Fee Current
PrepaidLicenseFeeCurrent
30472
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
195632
CY2024Q3 pmn Share Subscribed Subscriptions Receivable Current
ShareSubscribedSubscriptionsReceivableCurrent
500000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
12990
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
33217
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2941279
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
988641
CY2024Q3 pmn Accrued Legal Fees Current
AccruedLegalFeesCurrent
69510
CY2023Q4 pmn Accrued Legal Fees Current
AccruedLegalFeesCurrent
66254
CY2023Q4 pmn Deferred Financing Costs
DeferredFinancingCosts
99883
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
82275
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
101528
CY2024Q3 pmn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
578383
CY2023Q4 pmn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
691908
CY2024Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
172550
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
518704
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157134
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28249
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1059852
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1506526
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1166667
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
57341371
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13595987
CY2023Q4 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
1166667
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1087493
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
898262
CY2023Q4 pmn Accrued Legal Fees Current
AccruedLegalFeesCurrent
66254
CY2023Q4 pmn Deferred Financing Costs
DeferredFinancingCosts
99883
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
82275
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
101528
CY2024Q3 pmn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
578383
CY2023Q4 pmn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
691908
CY2024Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
172550
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
518704
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157134
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28249
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1059852
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1506526
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32689190
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18885254
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1166667
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
57341371
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13595987
CY2023Q4 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
1166667
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1087493
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
898262
CY2024Q3 pmn Deferred Share Units Outstanding
DeferredShareUnitsOutstanding
1061
CY2023Q4 pmn Deferred Share Units Outstanding
DeferredShareUnitsOutstanding
1061
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5450345
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
471843
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
63880270
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16133820
pmn Number Of Votes Per Common Share
NumberOfVotesPerCommonShare
1
CY2024Q3 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
6.00
CY2024Q3 pmn Mandatory Conversion Preferred Stock Value Outstanding
MandatoryConversionPreferredStockValueOutstanding
14000000.0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
29832984
CY2024Q3 pmn Share Subscribed Subscriptions Receivable Current
ShareSubscribedSubscriptionsReceivableCurrent
500000
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2645487
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
27687497
pmn Loss On Sale Of Common Shares And Warrants
LossOnSaleOfCommonSharesAndWarrants
3494536
CY2024Q3 pmn Deferred Share Units Outstanding
DeferredShareUnitsOutstanding
1061
CY2023Q4 pmn Deferred Share Units Outstanding
DeferredShareUnitsOutstanding
1061
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5450345
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
471843
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
63880270
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16133820
pmn Number Of Votes Per Common Share
NumberOfVotesPerCommonShare
1
CY2024Q3 pmn Mandatory Conversion Preferred Stock Value Outstanding
MandatoryConversionPreferredStockValueOutstanding
14000000.0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
29832984
CY2024Q3 pmn Share Subscribed Subscriptions Receivable Current
ShareSubscribedSubscriptionsReceivableCurrent
500000
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2645487
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
27687497
pmn Loss On Sale Of Common Shares And Warrants
LossOnSaleOfCommonSharesAndWarrants
3494536
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
57341371
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
422002
pmn Decrease In Fair Value Of Share Based Compensation Liability Increase In Additional Paid In Capital
DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital
81912
CY2024Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
340090
CY2023 pmn Share Based Compensation Liability Of Options At Reclassification On Change In Functional Currency
ShareBasedCompensationLiabilityOfOptionsAtReclassificationOnChangeInFunctionalCurrency
1768515
CY2023 pmn Decrease In Fair Value Of Share Based Compensation Liability Reduction In Share Based Compensation Expense
DecreaseInFairValueOfShareBasedCompensationLiabilityReductionInShareBasedCompensationExpense
332603
CY2023 pmn Decrease In Fair Value Of Share Based Compensation Liability Increase In Additional Paid In Capital
DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital
1013910
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
422002
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
57341371
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
422002
pmn Decrease In Fair Value Of Share Based Compensation Liability Increase In Additional Paid In Capital
DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital
81912
CY2024Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
340090
CY2023 pmn Share Based Compensation Liability Of Options At Reclassification On Change In Functional Currency
ShareBasedCompensationLiabilityOfOptionsAtReclassificationOnChangeInFunctionalCurrency
1768515
CY2023 pmn Decrease In Fair Value Of Share Based Compensation Liability Reduction In Share Based Compensation Expense
DecreaseInFairValueOfShareBasedCompensationLiabilityReductionInShareBasedCompensationExpense
332603
CY2023 pmn Decrease In Fair Value Of Share Based Compensation Liability Increase In Additional Paid In Capital
DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital
1013910
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
422002
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
121036
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
134191
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
202619
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
266701
pmn Cash Payments Related Party
CashPaymentsRelatedParty
443260
pmn Cash Payments Related Party
CashPaymentsRelatedParty
296590
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
9275825
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2360648
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3017080
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9632053
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30023675
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12370830
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22953751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861719
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
121036
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
134191
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
202619
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
266701
pmn Cash Payments Related Party
CashPaymentsRelatedParty
443260
pmn Cash Payments Related Party
CashPaymentsRelatedParty
296590
CY2023Q3 pmn Collaborative Arrangement Accruals For Royalty Payments
CollaborativeArrangementAccrualsForRoyaltyPayments
0
CY2016Q2 pmn Related Party Transaction Term Of Agreement
RelatedPartyTransactionTermOfAgreement
P3Y
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
9275825
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2360648
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3017080
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9632053
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30023675
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861719
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
57835201
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
57835201
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16165117
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46171024
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16165117
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16165117
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46171024
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16165117
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015634-index-headers.html Edgar Link pending
0001558370-24-015634-index.html Edgar Link pending
0001558370-24-015634.txt Edgar Link pending
0001558370-24-015634-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmn-20240930.xsd Edgar Link pending
pmn-20240930x10q.htm Edgar Link pending
pmn-20240930xex31d1.htm Edgar Link pending
pmn-20240930xex31d2.htm Edgar Link pending
pmn-20240930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
pmn-20240930_def.xml Edgar Link unprocessable
pmn-20240930_lab.xml Edgar Link unprocessable
pmn-20240930_pre.xml Edgar Link unprocessable
pmn-20240930x10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
0001558370-24-015634-index-headers.html Edgar Link pending
0001558370-24-015634-index.html Edgar Link pending
0001558370-24-015634.txt Edgar Link pending
0001558370-24-015634-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmn-20240930.xsd Edgar Link pending
pmn-20240930x10q.htm Edgar Link pending
pmn-20240930xex31d1.htm Edgar Link pending
pmn-20240930xex31d2.htm Edgar Link pending
pmn-20240930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
pmn-20240930_cal.xml Edgar Link unprocessable
pmn-20240930_def.xml Edgar Link unprocessable
pmn-20240930x10q_htm.xml Edgar Link completed
pmn-20240930_pre.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pmn-20240930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pmn-20240930_lab.xml Edgar Link unprocessable